IL23R and irritable bowel syndrome: Specifically, IL23R encodes the interleukin 23 receptor, and risankizumab, targeting interleukin 23, was repurposed as the treatment for Crohn’s disease (a subtype of IBD) from the original usage for psoriasis [11].